Activity Date: 04/07/2019
Over 800,000 people die by suicide world-wide every year and suicide was the second leading cause of death in 15-29-year-olds in the U.S. in 2016. Up to 90% of people who die by suicide have a diagnosable mental health or substance use disorder at time of death and will often come into contact with health professionals, including pharmacists, during their time of suicide risk. In fact, approximately 19% of people who die by suicide had contact with a mental health professional in the month prior to their death (Luoma, Martin & Pearson, 2002). Unfortunately, many health professionals including pharmacists have not received adequate suicide prevention training. For psychiatric pharmacists who work with this vulnerable population, suicide prevention education is more important than ever.
Suicide is a complex, multifaceted, biological, sociological, psychological, and societal problem with little training for prevention. As a major international health problem, it is estimated that suicide will contribute more than 2% to the global burden of disease by 2020. According to recently released data from the CDC, suicide rates are up over 30% in reporting states since 1999, and there were nearly 45,000 lives lost to suicide in 2016. While persons who die by suicide often have varying clinical presentations and needs, psychiatric clinical pharmacists have the opportunity to provide effective interventions for suicidality by addressing mental health and mitigating risk factors such as substance abuse.
In this pre-meeting workshop, participants will learn hands-on suicide risk assessment and prevention techniques, including helpful risk mitigation strategies and appropriate documentation. Advanced clinical situations will be presented, and participants will prepare an appropriate treatment plan for a patient who is having suicidal ideation by utilizing suicide assessment risk scales and accurately assessing a patient’s suicide risk level. Participants will also have the opportunity to discuss challenges they see in their own practice settings with regard to suicide risk assessment and prevention, and they will receive updates on evidence-based, suicide-specific practices to help prevent suicide.
To receive ACPE credit for the live session at the Annual Meeting, you must:
This course will be provided at the CPNP 2019 Annual Meeting, April 7-10, 2019. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at http://cpnp.org/mycpnp/transcript/acpe.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows 7 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Rosana Oliveira, PharmD, BCPS BCPP
Brandy Singer, PharmD, BCPP
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 3.0 contact hours of application-based continuing education credit from CPNP approved programming.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.